Company Filing History:
Years Active: 1997-2000
Title: The Innovations of Phillip B Maples
Introduction
Phillip B Maples is a notable inventor based in Waukegan, IL (US). He has made significant contributions to the field of biotechnology, particularly in the development of genetically altered human neutrophil precursor cells. With a total of 4 patents to his name, his work has the potential to impact medical treatments and therapies.
Latest Patents
Among his latest patents, one includes a composition comprising genetically altered human neutrophil precursor cells. This composition is characterized by at least about 16% human myeloblasts and promyelocytes derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow, or cord blood. Additionally, it contains less than about 5% colony-forming units (CFU) of at least about 50 cells. Another patent presents an alternative composition with at least about 16% CD15+CD11b- cells, where at least about 60% of these cells are myeloblasts and promyelocytes. Furthermore, he has developed a composition of human neutrophil precursor cells that have at least 37% myeloblasts and promyeloblasts, along with hematopoietic cell suspensions that include these precursor cells and at least one hematopoietic growth factor.
Career Highlights
Phillip B Maples has worked with prominent companies in the biotechnology sector, including Nexell Therapeutics Inc. and Baxter Healthcare Inc. His experience in these organizations has contributed to his expertise and innovation in the field.
Collaborations
Throughout his career, Phillip has collaborated with notable individuals such as James G Bender and Stephen L Smith. These collaborations have likely enhanced his research and development efforts.
Conclusion
Phillip B Maples is a distinguished inventor whose work in genetically altered human neutrophil precursor cells showcases his innovative spirit and dedication to advancing biotechnology. His contributions are poised to make a significant impact in the medical field.